Dr. Pinker is a professor of psychology at Harvard University. In my 22 years as a Harvard professor, I have not been afraid to bite the hand that feeds me. My 2014 essay “The Trouble With ...

Men are more likely to die from "broken heart syndrome" than women are, according to a new study published. Takotsubo Cardiomyopathy, also known as broken heart syndrome, is brought on by physical ...

In videos that are going viral on those platforms, typical facial features associated with Down syndrome are being superimposed over the faces of scantily clad women engaged in sexually suggestive ...

The global adrenogenital syndrome treatment market is poised for sustained growth, expected to expand from USD 14.2 billion in 2025 to USD 24.5 billion by 2035, registering a compound annual growth ...

How Has the Adrenogenital Syndrome Treatment Market Performed in Recent Years? The adrenogenital syndrome treatment market size has grown strongly in recent years. It is expected to grow from $12. ...

Since 2006 adrenogenital syndrome, galactosaemia and cystic fibrosis have been included in screening. Audiological screening of first-year children, which helps to diagnose hearing infringements in ...

She is the author of Qualified: How Competency Checking and Race Collide at Work The term “imposter syndrome” has become a cultural shorthand for self-doubt. We’re told it’s something to ...

The test can provide results in 48 minutes for diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital ... polycystic ovaries, and ...

The revenue for Crinecerfont is expected to reach an annual total of $466 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

Zydus recently received the Food and Drug Administration’s green light for fludrocortisone acetate tablets, 0.1 mg. Fludrocortisone acetate tablets are indicated as partial replacement therapy ...

Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing ...